Objective:Pancreatic ductal adenocarcinoma(PDAC)is a highly malignant gastrointestinal cancer with a 5-year survival rate of only 9%.Of PDAC patients,15%-20%are eligible for radical surgery.Gemcitabine is an important...Objective:Pancreatic ductal adenocarcinoma(PDAC)is a highly malignant gastrointestinal cancer with a 5-year survival rate of only 9%.Of PDAC patients,15%-20%are eligible for radical surgery.Gemcitabine is an important chemotherapeutic agent for patients with PDAC;however,the efficacy of gemcitabine is limited due to resistance.Therefore,reducing gemcitabine resistance is essential for improving survival of patients with PDAC.Identifying the key target that determines gemcitabine resistance in PDAC and reversing gemcitabine resistance using target inhibitors in combination with gemcitabine are crucial steps in the quest to improve survival prognosis in patients with PDAC.Methods:We constructed a human genome-wide CRISPRa/dCas 9 overexpression library in PDAC cell lines to screen key targets of drug resistance based on sgRNA abundance and enrichment.Then,co-IP,ChIP,ChIP-seq,transcriptome sequencing,and qPCR were used to determine the specific mechanism by which phospholipase D1(PLD1)confers resistance to gemcitabine.Results:PLD1 combines with nucleophosmin 1(NPM1)and triggers NPM1 nuclear translocation,where NPM1 acts as a transcription factor to upregulate interleukin 7 receptor(IL7R)expression.Upon interleukin 7(IL-7)binding,IL7R activates the JAK1/STAT5 signaling pathway to increase the expression of the anti-apoptotic protein,BCL-2,and induce gemcitabine resistance.The PLD1 inhibitor,Vu0155069,targets PLD1 to induce apoptosis in gemcitabine-resistant PDAC cells.Conclusions:PLD1 is an enzyme that has a critical role in PDAC-associated gemcitabine resistance through a non-enzymatic interaction with NPM1,further promoting the downstream JAK1/STAT5/Bcl-2 pathway.Inhibiting any of the participants of this pathway can increase gemcitabine sensitivity.展开更多
To explore the existence and distribution of nucleophosmin in the nuclear matrix and its co-localization with the other related gene products following HMBA treatment in the human hepatocarcinoma SMMC-7721 cells,the n...To explore the existence and distribution of nucleophosmin in the nuclear matrix and its co-localization with the other related gene products following HMBA treatment in the human hepatocarcinoma SMMC-7721 cells,the nuclear matrix of SMMC-7721 cells was extracted pre/post HMBA induced differentiation.2D PAGE proteomics analyses showed that nucleophosmin existed in the fractions of nuclear matrix proteins and was down-regulated after HMBA treatment with further confirmation by Western blot analysis.The immunofluorescence observation revealed that nucleophosmin located in the nuclear matrix,HMBA treatment altered its expression level and distribution profile.The co-localization of nucleophosmin with cancer-related genes and the products of oncogenes or tumor repression genes,including c-fos,c-myc,p53 and Rb,using laser scanning confocal microscopy,were evaluated,and substantial differences were observed following HMBA treatment.The results implies that nucleophosmin,as a nuclear matrix protein,the level of its expression and the colocalization with cancer-related gene products may play an important role during the differentiation of SMMC-7721 cell.展开更多
本研究旨在分析NPM1和FLT3-ITD突变与急性髓系白血病患者外周血白细胞数及骨髓原始细胞百分比的相关性。回顾分析我中心2009年1月至2011年12月份初治正常核型急性髓系白血病患者51例,其中男性22例,女性29例,中位年龄47岁(14-83岁)。采...本研究旨在分析NPM1和FLT3-ITD突变与急性髓系白血病患者外周血白细胞数及骨髓原始细胞百分比的相关性。回顾分析我中心2009年1月至2011年12月份初治正常核型急性髓系白血病患者51例,其中男性22例,女性29例,中位年龄47岁(14-83岁)。采用聚合酶链式反应检测NPM1及FLT3-ITD突变状态。结果表明,与无NPM1突变患者相比,突变者初诊时外周血白细胞数较多(30.7×109/L vs 8.6×109/L,P=0.002);FLT3-ITD突变患者较无突变患者具有更多的外周血白细胞数(42.38×109/L vs 11.45×109/L,P=0.033)及更高的骨髓原始细胞百分比(74.0%vs 60.25%,P=0.036)。外周血白细胞数及骨髓原始细胞百分比在NPM1、FLT3-ITD无突变组、单独NPM1突变组、单独FLT3-ITD突变组到NPM1、FLT3-ITD双突变组逐步升高(均P<0.05)。白细胞数大于12.55×109/L的患者NPM1突变率明显升高(P=0.002),大于37.85×109/L者FLT3-ITD突变率明显升高(P=0.033);原始细胞比例大于72.25%的FLT3-ITD突变率明显升高(P=0.008)。NPM1突变患者首疗程完全缓解率(CR)明显高于无突变者(78.13%vs 40.0%,χ2=4.651,P=0.031)。结论:NPM1及FLT3-ITD突变患者白细胞计数及原始细胞比例大,提示NPM1与FLT3-ITD突变均可能促进白血病细胞增殖,且二者可能具有协同效应。展开更多
基金supported by the National Key Research and Development Program of China(Grant No.2021YFA1201100)the National Natural Science Foundation of China(Grant Nos.82103006,82030092,81720108028,82072657,82072716,82103003,82173295,81871968,81871978,82072691,and 82103222)+1 种基金the Tianjin Hygiene Healthy Science and Technology Project(Grant No.TJWJ2022MS007)the Science&Technology Development Fund of Tianjin Education Commission for Higher Education(Grant No.2020KJ141).
文摘Objective:Pancreatic ductal adenocarcinoma(PDAC)is a highly malignant gastrointestinal cancer with a 5-year survival rate of only 9%.Of PDAC patients,15%-20%are eligible for radical surgery.Gemcitabine is an important chemotherapeutic agent for patients with PDAC;however,the efficacy of gemcitabine is limited due to resistance.Therefore,reducing gemcitabine resistance is essential for improving survival of patients with PDAC.Identifying the key target that determines gemcitabine resistance in PDAC and reversing gemcitabine resistance using target inhibitors in combination with gemcitabine are crucial steps in the quest to improve survival prognosis in patients with PDAC.Methods:We constructed a human genome-wide CRISPRa/dCas 9 overexpression library in PDAC cell lines to screen key targets of drug resistance based on sgRNA abundance and enrichment.Then,co-IP,ChIP,ChIP-seq,transcriptome sequencing,and qPCR were used to determine the specific mechanism by which phospholipase D1(PLD1)confers resistance to gemcitabine.Results:PLD1 combines with nucleophosmin 1(NPM1)and triggers NPM1 nuclear translocation,where NPM1 acts as a transcription factor to upregulate interleukin 7 receptor(IL7R)expression.Upon interleukin 7(IL-7)binding,IL7R activates the JAK1/STAT5 signaling pathway to increase the expression of the anti-apoptotic protein,BCL-2,and induce gemcitabine resistance.The PLD1 inhibitor,Vu0155069,targets PLD1 to induce apoptosis in gemcitabine-resistant PDAC cells.Conclusions:PLD1 is an enzyme that has a critical role in PDAC-associated gemcitabine resistance through a non-enzymatic interaction with NPM1,further promoting the downstream JAK1/STAT5/Bcl-2 pathway.Inhibiting any of the participants of this pathway can increase gemcitabine sensitivity.
文摘To explore the existence and distribution of nucleophosmin in the nuclear matrix and its co-localization with the other related gene products following HMBA treatment in the human hepatocarcinoma SMMC-7721 cells,the nuclear matrix of SMMC-7721 cells was extracted pre/post HMBA induced differentiation.2D PAGE proteomics analyses showed that nucleophosmin existed in the fractions of nuclear matrix proteins and was down-regulated after HMBA treatment with further confirmation by Western blot analysis.The immunofluorescence observation revealed that nucleophosmin located in the nuclear matrix,HMBA treatment altered its expression level and distribution profile.The co-localization of nucleophosmin with cancer-related genes and the products of oncogenes or tumor repression genes,including c-fos,c-myc,p53 and Rb,using laser scanning confocal microscopy,were evaluated,and substantial differences were observed following HMBA treatment.The results implies that nucleophosmin,as a nuclear matrix protein,the level of its expression and the colocalization with cancer-related gene products may play an important role during the differentiation of SMMC-7721 cell.
文摘本研究旨在分析NPM1和FLT3-ITD突变与急性髓系白血病患者外周血白细胞数及骨髓原始细胞百分比的相关性。回顾分析我中心2009年1月至2011年12月份初治正常核型急性髓系白血病患者51例,其中男性22例,女性29例,中位年龄47岁(14-83岁)。采用聚合酶链式反应检测NPM1及FLT3-ITD突变状态。结果表明,与无NPM1突变患者相比,突变者初诊时外周血白细胞数较多(30.7×109/L vs 8.6×109/L,P=0.002);FLT3-ITD突变患者较无突变患者具有更多的外周血白细胞数(42.38×109/L vs 11.45×109/L,P=0.033)及更高的骨髓原始细胞百分比(74.0%vs 60.25%,P=0.036)。外周血白细胞数及骨髓原始细胞百分比在NPM1、FLT3-ITD无突变组、单独NPM1突变组、单独FLT3-ITD突变组到NPM1、FLT3-ITD双突变组逐步升高(均P<0.05)。白细胞数大于12.55×109/L的患者NPM1突变率明显升高(P=0.002),大于37.85×109/L者FLT3-ITD突变率明显升高(P=0.033);原始细胞比例大于72.25%的FLT3-ITD突变率明显升高(P=0.008)。NPM1突变患者首疗程完全缓解率(CR)明显高于无突变者(78.13%vs 40.0%,χ2=4.651,P=0.031)。结论:NPM1及FLT3-ITD突变患者白细胞计数及原始细胞比例大,提示NPM1与FLT3-ITD突变均可能促进白血病细胞增殖,且二者可能具有协同效应。
